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Background. Inﬂammation in the Brugada syndrome (BrS) and its clinical implication have been little studied. Aims. To assess the
level of inﬂammation in BrS patients. Methods. All studied BrS patients underwent blood samples drawn for C-reactive protein
(CRP) levels at admission, prior to any invasive intervention. Patients with a previous ICD placement were controlled to exclude
thosewith a recent (<14 days) shock. We divided subjects into symptomatic (syncope or aborted sudden death) and asymptomatic
groups. In a multivariable analysis, we adjusted for signiﬁcant variables (age, CRP ≥ 2mg/L). Results. Fifty-four subjects were
studied (mean age 45 ± 13 years, 49 (91%) male). Twenty (37%) were symptomatic. Baseline characteristics were similar in both
groups. Mean CRP level was 1,4 ± 0,9mg/L in asymptomatic and 2,4 ± 1,4mg/L in symptomatic groups (P = .003). In the
multivariate model, CRP concentrations ≥ 2mg/L remained an independent marker for being symptomatic (P = .018; 95% CI:
1.3 to 19.3). Conclusion. Inﬂammation seems to be more active in symptomatic BrS. C-reactive protein concentrations ≥ 2mg/L
might be associated with the previous symptoms in BrS. The value of inﬂammation as a risk factor of arrhythmic events in BrS
needs to be studied.
1.Introduction
The Brugadasyndrome (BrS)is aninherited cardiac disorder
occurring particularly in young, apparently healthy individ-
uals and is associated with a variety of arrhythmias, mainly
ventricular tachyarrhythmias that can induce syncope or
sudden cardiac arrest (SCA) [1]. Patients with documented
cardiac arrest should receive an implantable cardioverter-de-
ﬁbrillator(ICD)[2].Intheremainingsubjects,thebestman-
agement is still a challenge. Long-term follow-up of this sub-
group of patients has revealed a low accuracy of stratiﬁcation
based on only one risk factor [3]. A multiparametric ap-
proach, including more than one risk factor, may increase
the likelihood to predict ventricular arrhythmias that can be
prevented by an ICD.
Increased body of evidence links lethal ventricular
arrhythmias with inﬂammatory states [4]. It is known that
arrhythmic events in BrS are triggered by febrile states,
independent of the etiology [5]. Amin et al. have proposed
that “research is needed on the study of the in vivo eﬀects of
fever and its various aspects,” including “inﬂammatory cells
and cytokines” [6]. C-reactive protein (CRP) is an acute-
phasereactant,whoselevelsriseinresponsetoinﬂammation.
Serum levels of CRP have been shown to be increased
soon after the occurrence of ventricular arrhythmias in
other arrhythmogenic diseases like arrhythmogenic right
ventricular dysplasia/cardiomyopathy (ARVD/C) [7]. Serum
levels of CRP in BrS and their possible clinical implications
have not been studied before. We evaluated levels of CRP in
a cohort of subjects with BrS.2 Cardiology Research and Practice
Flowchart of the study population
Asymptomatic BrS pts n = 34 Symptomatic BrS pts n = 20
Syncope n = 17 Aborted SCD n = 3
Study population n = 54
CRP: 1.4 ± 0.9mg/L CRP: 2.4 ± 1.4mg/L
CRP: 2.12 ± 1.4mg/L CRP: 4 ± 2mg/L
Figure1:Fifty-fourpatientswithBrSweredividedintotwogroupsaccordingtotheclinicalfeature.BrS:Brugadasyndrome;CRP:C-reactive
protein.
2. Methods
2.1. Study Population. Patients of our BrS registry were care-
fully analyzed in terms of past medical history. They were
referred for three main reasons: family screening of a BrS in-
dex case, unexplained syncope, or aborted SCA. At admis-
sion,acompleteclinicalhistory,includingfamilyantecedents
withemphasis onSCA, wasobtained. Allpatients underwent
physical examination and cardiac work-up that included
ECG, 2D echocardiography, signal averaged ECG (SAECG),
ajmaline challenge (in the absence of spontaneous type 1
ECG pattern), and at least two of the following cardiac imag-
ing studies: right ventricular angiography, cardiac MRI, or
ventricular radionuclide imaging. The diagnosis of BrS was
made if ECG displayed coved-type ST-segment elevation,
either spontaneously or after a sodium channel blocker chal-
lenge, in at least one right precordial lead (V1–V3)i nc o n -
junction with a documented ventricular ﬁbrillation (VF),
self-terminating polymorphic ventricular tachycardia (VT),
agonalnocturnalrespiration,syncope,abortedSCA,orfami-
ly history (<45 years) of SCA. Asymptomatic patients were
compared with symptomatic (syncope and aborted SCA).
Study protocol was approved by the Institutional Review
Board of Piti´ e-Salpˆ etri` ere Hospital, and informed consent
was obtained from each participant.
2.2. Blood Testing. At admission, for work-up and before any
cardiac intervention such as drug challenge, EP study, car-
diaccatheterization,orICDimplantation;aspartoftherout-
ine blood sampling, CRP concentration was measured in
each patient by immunoturbidimetric method (Integra 400
Roche, France). For characterization of inﬂammatory state,
only CRP measurements were performed. Data were collect-
ed retrospectively, and we verify that no recent arrhythmic
event had occurred prior to blood sample testing. In those
patients with established diagnosis of BrS and carriers of an
ICD, a device interrogation was performed to exclude recent
(<14 days) shock discharge.
2.3. Study Covariates. Hypertension was deﬁned as diastolic
blood pressure ≥ 90mmHg and/or systolic blood pressure ≥
140mmHg and/or a patient on antihypertensive medication.
Diabetes mellitus was based on a fasting blood sugar ≥
7mmol/Land/oroninsulinregimenoronanyotherantidia-
betic treatment. Smoking was classiﬁed into ever and never
smokers. Lipid lowering treatment was statin treatment with
anti-inﬂammatory properties. Aspirin, even when a low dose
is used, has the potential to inﬂuence CRP release [8]. Bru-
gada-ECG pattern displayed coved-type ST-segment eleva-
tion in V1 through V3. Wide QRS was duration of QRS
>120ms. Other covariates of interest were age, atrial ﬁbril-
lation (AF), drug challenge by ajmaline test, family history of
SCD, and ICD placement for high-risk status or for secon-
dary prevention.
2.4.StatisticalAnalysis. Continuousvariableswereexpressed
asmean±SDiftheydemonstratedanormaldistributionand
as median (range) otherwise. Means of continuous variables
that showed normal distribution were compared with the
Student’s t-test for independent samples. Continuous vari-
ablesthatdidnotshowanormaldistributionwerecompared
using the Mann-Whitney U test. Categorical variables were
summarized as proportions and compared using the χ2 test
or the Fischer exact test if cell counts were less than 5.
For the multivariate model, only factors that attained statis-
tical signiﬁcance (P<. 1) in the univariate analysis were in-
cluded. A 2-tailed P value <. 05 was considered statistically
signiﬁcant. Statistical analysis was performed with SPSS ver-
sion 11.0.1 software(SPSS Inc). Figure 2 wasperformedwith
Statistica v6.0 (StatSoft Inc).
3. Results
3.1. Characteristics of the Baseline Population. The study
sample consisted of 54 patients, with a mean age of 45 ± 13
years old and 49 (91%) being male. Twenty (37%) were sym-
ptomatic (17 syncope and 3 aborted SCA) (Figure 1). Base-
line characteristics were similar in both groups apart from
the younger age of those in the asymptomatic group (40±12
versus 53 ± 10, P = 0.001, Table 1) .T h ep r e v a l e n c eo fc a r -
diovascular risk factors in the whole cohort was 15%Cardiology Research and Practice 3
Table 1: Baseline characteristics of asymptomatic and symptomatic BrS patients.
Asymptomatic (n = 34) Symptomatic (n = 20) P value 95% CI
Univariate analysis Multivariate analysis
Age (years) 40 ±12 53 ±10 .001 .009 1.56–22.08
Male 32 (94%) 17 (85%) ns —
Hypertension 3 (9%) 5 (25%) ns —
Hypercholesterolemia 6 (18%) 3 (15%) ns —
Smokers 6 (18%) 2 (10%) ns —
Diabetes 0 1 (5%) ns —
Statin 1 (3%) 2 (10%) ns —
Aspirin 0 1 (5%) ns —
First-degree AV block 4 (12%) 5 (25%) ns —
QRS > 120ms 10 (29%) 3 (15%) ns —
Type 1 ECG pattern 19 (56%) 14 (70%) ns —
CRP ≥ 2mg/L 11 (32%) 15 (75%) .003 .018 1.32–19.31
Mean
±SE
±1.96∗SE
Without
symptom
With
symptom
1
1.2
1.4
1.6
1.8
2
2.2
2.4
2.6
2.8
3
3.2
C
R
P
(
m
g
/
L
)
P = 0.003
Figure 2: CRP concentrations in the BrS patients without (left
diagram) and with (right diagram) symptoms (syncope or SCA)
were signiﬁcantly diﬀerent. CRP: C-reactive protein; BrS: Brugada
syndrome; SCA: sudden cardiac arrest.
hypertension, 15% smokers, 17% hypercholesterolemia, and
2% diabetes with no diﬀerences among groups (Table 1).
Fifteen (28%) patients had family history of SCA, and 33
(61%) had spontaneous, diagnostic, coved-type ECG.
3.2. Comparison between Patients with and without Symp-
toms. Asymptomatic and symptomatic patients were com-
parable in gender, cardiovascular risk factors, and main ECG
features (ﬁrst-degree atrioventricular block, wide QRS, and
coved type ST-segment elevation in right precordial leads).
Mean age and CRP levels were the only parameters signiﬁ-
cantly diﬀerent in univariate analysis between both groups.
In Table 1 is also shown the multivariate analysis for predi-
ctors of being symptomatic. A signiﬁcant value was still
found for age and levels of CRP ≥ 2mg/L(P = .009, CI 95%
1.56–22.08, and P = .018, CI 95% 1.32–19.31, resp.).
3.3. Clinical Features of Patients with ICD. Implantation of
an ICD started in our centre before current recommenda-
tions [2]. Therefore, 10 asymptomatic patients (29%) were
implanted for high-risk status (spontaneous coved-type ST-
segment elevation in conjunction with either family history
of SCA or positive EP study). None of these 10 patients have
experienced ICD shock, and their electrogram memories did
not show ventricular arrhythmias. In 16 (80%) symptomatic
patients, an ICD was implanted either before hospitalization
(>3months)orafterbloodsamplingwastakenforCRP.Four
out of 16 (25%) had appropriate ICD shock during follow-
up.
3.4. Inﬂammatory Pattern and Its Relationship with Car-
diac Arrhythmic Events. As previously mentioned, levels of
CRP were signiﬁcantly diﬀerent in both groups, asymp-
tomatic versus symptomatic subjects. The mean CRP lev-
els (Figure 2)w e r e1 , 4 ± 0,9mg/L in asymptomatic and
2,4 ± 1,4mg/L in symptomatic group (P = .003). CRP
concentration ≥ 2mg/L was an independent marker for
being symptomatic (P = .018; 95% CI: 1.3 to 19.3)
(Table 2). A CRP concentration ≥ 2mg/L was signiﬁcantly
associated with type 1 ECG pattern (P = .022), syn-
cope (P = .025), syncope and/or aborted SCA (P =
.018), and the decision to implant an ICD (P = .003)
inunivariateanalysis.Aftermultivariateanalysis,onlyoverall
symptoms (syncope and/or resuscitated SCA) remained sig-
niﬁcantly diﬀerent (P = .039, 95% CI: 1.07–18,79) (Table 2).
4. Discussion
The aim of this study was to assess the inﬂammatory proﬁle
measured by CRP in individuals with BrS. The study also4 Cardiology Research and Practice
Table 2: Demographic and clinical characteristics of the Brugada patients with CRP < or ≥ 2mg/l.
CRP < 2mg/L(n = 28) CRP ≥ 2mg/L(n = 26)
P value
95%CI
Univariate analysis Multivariate
analysis
Age (years) 44 ±14 46 ±12 ns —
Male 24 (86%) 25 (96%) ns —
Coved-type ECG 13 (46%) 20 (77%) .022 ns
VT/FV 1 (4%) 4 (15%) ns —
Family history 5 (18%) 10 (38%) ns —
Syncope 5 (18%) 12 (46%) .025 ns
Aborted SCA 0 3 (12%) ns
Overall symptoms
(syncope and/or
aborted SCA)
5 (18%) 15 (58%) .018 0.039 1.07–18.79
ICD† 8 (29%) 18 (69%) .003 ns
CRP: C-reactive protein; VT: ventricular tachycardia; FV: ventricular ﬁbrillation; SCD: sudden cardiac death; ICD: implantable cardioverter-deﬁbrillator;
†placement of ICD was done before (>3 months) or after blood testing for serum CRP concentration.
looked at the association between past history of arrhythmic
events and CRP level.
4.1. Major Findings. This study shows that patients with BrS
syndrome and life-threatening symptoms such as syncope
or sudden death have more active inﬂammation than those
without symptoms. Moreover, a CRP level ≥ 2mg/Lismore
frequent in the presence of previous cardiac arrhythmic
events.
4.2. Inﬂammation and Cardiovascular Outcomes. CRP is a
biomarker of inﬂammation, and high levels have been asso-
ciated with an increased risk of all-cause mortality [9]. It
predicts cardiovascular events such as stroke, coronary heart
disease, and peripheral vascular disease [10, 11]. Serum CRP
levels greater than 3mg/L have been shown to predict these
cardiovascular events [12], and anti-inﬂammatory agents
such as statins have demonstrated a reduction of cardiovas-
cular mortality in patients with normal lipid proﬁle [13]. It
is well known that systemic inﬂammation is associated with
arrhythmias. This association has been extensively studied in
atrial ﬁbrillation (AF) [14]. It has been shown that increas-
ed CRP levels are associated with greater risk of AF recur-
rence after electrical cardioversion [15]. Moreover, dilated
cardiomyopathy patients with AF have higher inﬂammatory
activation than those without AF [16]. Ventricular arrhyth-
mia incidence is associated with signiﬁcantly elevated pro-
inﬂammatory markers such as IL-6 and high-sensitive CRP
in implantable cardioverter-deﬁbrillator (ICD) patients with
structural heart disease [4]. Enhanced inﬂammatory res-
ponse is related to the development of ventricular arrhyth-
mias after ST-elevation myocardial infarction. During acute
myocardial ischemia, patients with malignant ventricular ar–
rhythmias experience higher systemic inﬂammation than
those without them [17]. Consistent with the later, statins
which have anti-inﬂammatory properties [18] are associated
with decreased incidence of VT [19–22]. However, recent
data has suggested that inﬂammatory biomarkers such as IL-
6,TNF-alpha,hsCRP,ﬁbrinogen,andBNParenotpredictive
of intermediate-term risk of ventricular tachyarrhythmias in
stable chronic heart failure [23]. Regarding the value of
inﬂammation in predicting SCA in apparently healthy pop-
ulations, controversial issues have been reported. Empana
et al. have not found any association between inﬂammatory
biomarkers and SCA in middle-aged men whereas other data
suggest that CRP levels may be useful in identifying ap-
parently healthy men who are at an increased long-term risk
of SCD [24, 25]. Whether inﬂammatory activation is the
cause or the consequence of ventricular arrhythmias is un-
clear. We have reported high CRP concentration in ARVD/C
soon after VT with a clear tendency to decrease its level after
the event [7].
4.3.InﬂammationandtheBrugadaSyndrome. Wefoundthat
a single plasma value of CRP concentration is robustly asso-
ciated with either syncope or SCA in BrS. Studies assessing
inﬂammatory patterns in BrS have reported controversial
ﬁndings.Onedidnotdetectinﬂammatorychangesincardiac
biopsies [26]. Others found locally restricted inﬂammation
due to parvovirus B19 [27, 28]. Frustaci et al. reported histo-
logical evidence of a prevalent or localized right ventricular
myocarditis in 14 out of 18BrS patients who underwent
endomyocardial biopsy [29]. The range of CRP between 1
and 3mg/L was considered intermediate risk. In the symp-
tomatic group of patients, the median level of CRP was
2mg/L, which is above the value known in the general pop-
ulation [9–12]. Therefore, we hypothesized that this value of
CRPmaydiscriminatebetweenindividualswithandwithout
symptoms. This hypothesis was conﬁrmed by the ﬁnding
that symptoms were more frequent in the subgroup with
CRP levels ≥ 2mg/L (Table 2). Interestingly, when adjust-
ed for age, CRP ≥ 2mg/L remained an independent factor
for being symptomatic (Table 1). The signiﬁcant associa-
tion of CRP concentration with symptoms suggests thatCardiology Research and Practice 5
inﬂammation might play a role in the pathophysiology of
arrhythmias in BrS.
We consider this ﬁnding relevant for risk stratiﬁcation in
BrS. With an increasing number of patients being diagnosed
withBrS,ourknowledgehasalsogrownineverysingleaspect
of this disease. However, estimation of the likelihood to die
suddenly remains diﬃcult in the absence of resuscitated SCA
[30]. For example, although all registries agree on the fact
that patients with syncope have a poor prognosis, it has been
documented that some syncope episodes in BrS patients are
in fact due to a vasovagal mechanism [31, 32]. Thus, the de-
cision to implant an ICD in syncope-related BrS patients,
eveninthesettingofEP-inducedVF,ischallengingwhentak-
ing into account the incidence of ICD-related complications,
which is up to 28%, and death-related ICD malfunction [33,
34]. Therefore, a multiparametric approach consisting in
considering diagnostic type 1 ECG pattern in conjunction
with syncope and at least one other risk factor has been sug-
gested[3]. To summarize, the risk/beneﬁt ratio of ICD place-
ment in this young population is diﬃcult to estimate [35].
Therefore, there is dire need for de novo risk markers for ar-
rhythmicevents.Thesedatashowasharpdeparturefromthe
current view that BrS has a polyfactorial pathogenesis which
may include inﬂammatory pathway. Indeed, knowledge re-
gardingtheclinicalspectrumofpatientswithaBrugadaECG
is important to implement eﬀective risk stratiﬁcation and
management [36, 37]. The results presented herein may be
useful to identify high-risk patients in need of primary or
secondary prevention by an ICD and during the follow-up
of implanted patients to detect those at risk to present ven-
tricular arrhythmias. However, larger clinical trials are need-
ed to conﬁrm the increase of inﬂammatory activity in symp-
tomatic Brugada syndrome.
Study Limitations. The strength of the study is that it is the
ﬁrsttoourknowledgetoevaluateCRPasamarkerofinﬂam-
mation in BrS. This may help provide a better understanding
of the large spectrum of the disease. However, there are some
potential limitations whichmerit consideration.First,wedid
not use the nephelometric technique assessing high sensiti-
vity C-reactive protein (hs-CRP) which is about a 10-fold
more sensitive than the immunoturbidimetric assay used in
this study. Secondly, few patients in our series (11 out of 54
(20%)) have been genotyped and only one displayed a muta-
tion in SCN5A gene. Therefore, a correlation between geno-
type and inﬂammation could not be established. This is a
very pertinent lack of information as there is a bunch of lit-
eratureshowingthatloss-of-functionSCN5Amutationslead
to ﬁbrosis and structural heart disease [38, 39], emphasizing
that CRP might rise via this pathway.
5. Conclusion
CRP levels are increased in symptomatic patients with BrS.
The causative role of inﬂammation in occurrence of arrhyth-
mic events in this disease needs to be further studied.
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